PMC:7600245 / 91532-92003 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T426","span":{"begin":43,"end":46},"obj":"Body_part"}],"attributes":[{"id":"A426","pred":"fma_id","subj":"T426","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":"Figure 3 Chemical structures of potential RNA polymerase inhibitors, all of which are nucleoside derivatives that undergo tri-phosphorylation activation to form the corresponding nucleoside triphosphate metabolites as the active forms. Emtricitabine is being tested in COVID-19 patients in combination with tenofovir disoproxil or tenofovir alafenamide. The activation schemes for tenofovir disoproxil or tenofovir alafenamide are provided in the supplementary document."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T424","span":{"begin":270,"end":278},"obj":"Disease"}],"attributes":[{"id":"A424","pred":"mondo_id","subj":"T424","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Figure 3 Chemical structures of potential RNA polymerase inhibitors, all of which are nucleoside derivatives that undergo tri-phosphorylation activation to form the corresponding nucleoside triphosphate metabolites as the active forms. Emtricitabine is being tested in COVID-19 patients in combination with tenofovir disoproxil or tenofovir alafenamide. The activation schemes for tenofovir disoproxil or tenofovir alafenamide are provided in the supplementary document."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T921","span":{"begin":143,"end":153},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T922","span":{"begin":223,"end":229},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T923","span":{"begin":260,"end":266},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T924","span":{"begin":359,"end":369},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"Figure 3 Chemical structures of potential RNA polymerase inhibitors, all of which are nucleoside derivatives that undergo tri-phosphorylation activation to form the corresponding nucleoside triphosphate metabolites as the active forms. Emtricitabine is being tested in COVID-19 patients in combination with tenofovir disoproxil or tenofovir alafenamide. The activation schemes for tenofovir disoproxil or tenofovir alafenamide are provided in the supplementary document."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T95370","span":{"begin":43,"end":68},"obj":"Chemical"},{"id":"T4303","span":{"begin":58,"end":68},"obj":"Chemical"},{"id":"T38829","span":{"begin":87,"end":97},"obj":"Chemical"},{"id":"T9189","span":{"begin":180,"end":203},"obj":"Chemical"},{"id":"T3062","span":{"begin":180,"end":190},"obj":"Chemical"},{"id":"T54673","span":{"begin":191,"end":203},"obj":"Chemical"},{"id":"T64553","span":{"begin":204,"end":215},"obj":"Chemical"},{"id":"T52517","span":{"begin":237,"end":250},"obj":"Chemical"},{"id":"T22591","span":{"begin":308,"end":328},"obj":"Chemical"},{"id":"T16179","span":{"begin":308,"end":317},"obj":"Chemical"},{"id":"T62835","span":{"begin":332,"end":353},"obj":"Chemical"},{"id":"T22175","span":{"begin":332,"end":341},"obj":"Chemical"},{"id":"T71480","span":{"begin":382,"end":402},"obj":"Chemical"},{"id":"T16181","span":{"begin":382,"end":391},"obj":"Chemical"},{"id":"T59872","span":{"begin":406,"end":427},"obj":"Chemical"},{"id":"T12220","span":{"begin":406,"end":415},"obj":"Chemical"}],"attributes":[{"id":"A50964","pred":"chebi_id","subj":"T95370","obj":"http://purl.obolibrary.org/obo/CHEBI_37416"},{"id":"A45254","pred":"chebi_id","subj":"T4303","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A80792","pred":"chebi_id","subj":"T38829","obj":"http://purl.obolibrary.org/obo/CHEBI_33838"},{"id":"A60919","pred":"chebi_id","subj":"T9189","obj":"http://purl.obolibrary.org/obo/CHEBI_17326"},{"id":"A18697","pred":"chebi_id","subj":"T3062","obj":"http://purl.obolibrary.org/obo/CHEBI_33838"},{"id":"A18384","pred":"chebi_id","subj":"T54673","obj":"http://purl.obolibrary.org/obo/CHEBI_18036"},{"id":"A74329","pred":"chebi_id","subj":"T64553","obj":"http://purl.obolibrary.org/obo/CHEBI_25212"},{"id":"A20199","pred":"chebi_id","subj":"T52517","obj":"http://purl.obolibrary.org/obo/CHEBI_31536"},{"id":"A19240","pred":"chebi_id","subj":"T22591","obj":"http://purl.obolibrary.org/obo/CHEBI_63717"},{"id":"A5584","pred":"chebi_id","subj":"T16179","obj":"http://purl.obolibrary.org/obo/CHEBI_134504"},{"id":"A93165","pred":"chebi_id","subj":"T16179","obj":"http://purl.obolibrary.org/obo/CHEBI_63625"},{"id":"A68244","pred":"chebi_id","subj":"T16179","obj":"http://purl.obolibrary.org/obo/CHEBI_63716"},{"id":"A85694","pred":"chebi_id","subj":"T62835","obj":"http://purl.obolibrary.org/obo/CHEBI_90926"},{"id":"A27141","pred":"chebi_id","subj":"T22175","obj":"http://purl.obolibrary.org/obo/CHEBI_134504"},{"id":"A5896","pred":"chebi_id","subj":"T22175","obj":"http://purl.obolibrary.org/obo/CHEBI_63625"},{"id":"A33177","pred":"chebi_id","subj":"T22175","obj":"http://purl.obolibrary.org/obo/CHEBI_63716"},{"id":"A97901","pred":"chebi_id","subj":"T71480","obj":"http://purl.obolibrary.org/obo/CHEBI_63717"},{"id":"A16221","pred":"chebi_id","subj":"T16181","obj":"http://purl.obolibrary.org/obo/CHEBI_134504"},{"id":"A89599","pred":"chebi_id","subj":"T16181","obj":"http://purl.obolibrary.org/obo/CHEBI_63625"},{"id":"A49096","pred":"chebi_id","subj":"T16181","obj":"http://purl.obolibrary.org/obo/CHEBI_63716"},{"id":"A11915","pred":"chebi_id","subj":"T59872","obj":"http://purl.obolibrary.org/obo/CHEBI_90926"},{"id":"A26555","pred":"chebi_id","subj":"T12220","obj":"http://purl.obolibrary.org/obo/CHEBI_134504"},{"id":"A67328","pred":"chebi_id","subj":"T12220","obj":"http://purl.obolibrary.org/obo/CHEBI_63625"},{"id":"A47120","pred":"chebi_id","subj":"T12220","obj":"http://purl.obolibrary.org/obo/CHEBI_63716"}],"text":"Figure 3 Chemical structures of potential RNA polymerase inhibitors, all of which are nucleoside derivatives that undergo tri-phosphorylation activation to form the corresponding nucleoside triphosphate metabolites as the active forms. Emtricitabine is being tested in COVID-19 patients in combination with tenofovir disoproxil or tenofovir alafenamide. The activation schemes for tenofovir disoproxil or tenofovir alafenamide are provided in the supplementary document."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T186","span":{"begin":127,"end":142},"obj":"http://purl.obolibrary.org/obo/GO_0016310"}],"text":"Figure 3 Chemical structures of potential RNA polymerase inhibitors, all of which are nucleoside derivatives that undergo tri-phosphorylation activation to form the corresponding nucleoside triphosphate metabolites as the active forms. Emtricitabine is being tested in COVID-19 patients in combination with tenofovir disoproxil or tenofovir alafenamide. The activation schemes for tenofovir disoproxil or tenofovir alafenamide are provided in the supplementary document."}

{"project":"LitCovid-sentences","denotations":[{"id":"T739","span":{"begin":0,"end":236},"obj":"Sentence"},{"id":"T740","span":{"begin":237,"end":354},"obj":"Sentence"},{"id":"T741","span":{"begin":355,"end":471},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Figure 3 Chemical structures of potential RNA polymerase inhibitors, all of which are nucleoside derivatives that undergo tri-phosphorylation activation to form the corresponding nucleoside triphosphate metabolites as the active forms. Emtricitabine is being tested in COVID-19 patients in combination with tenofovir disoproxil or tenofovir alafenamide. The activation schemes for tenofovir disoproxil or tenofovir alafenamide are provided in the supplementary document."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3957","span":{"begin":279,"end":287},"obj":"Species"},{"id":"3958","span":{"begin":87,"end":97},"obj":"Chemical"},{"id":"3959","span":{"begin":180,"end":203},"obj":"Chemical"},{"id":"3960","span":{"begin":237,"end":250},"obj":"Chemical"},{"id":"3961","span":{"begin":308,"end":328},"obj":"Chemical"},{"id":"3962","span":{"begin":332,"end":341},"obj":"Chemical"},{"id":"3963","span":{"begin":342,"end":353},"obj":"Chemical"},{"id":"3964","span":{"begin":382,"end":402},"obj":"Chemical"},{"id":"3965","span":{"begin":406,"end":415},"obj":"Chemical"},{"id":"3966","span":{"begin":416,"end":427},"obj":"Chemical"},{"id":"3967","span":{"begin":270,"end":278},"obj":"Disease"}],"attributes":[{"id":"A3957","pred":"tao:has_database_id","subj":"3957","obj":"Tax:9606"},{"id":"A3958","pred":"tao:has_database_id","subj":"3958","obj":"MESH:D009705"},{"id":"A3960","pred":"tao:has_database_id","subj":"3960","obj":"MESH:D000068679"},{"id":"A3961","pred":"tao:has_database_id","subj":"3961","obj":"MESH:D000068698"},{"id":"A3962","pred":"tao:has_database_id","subj":"3962","obj":"MESH:D000068698"},{"id":"A3964","pred":"tao:has_database_id","subj":"3964","obj":"MESH:D000068698"},{"id":"A3965","pred":"tao:has_database_id","subj":"3965","obj":"MESH:D000068698"},{"id":"A3967","pred":"tao:has_database_id","subj":"3967","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Figure 3 Chemical structures of potential RNA polymerase inhibitors, all of which are nucleoside derivatives that undergo tri-phosphorylation activation to form the corresponding nucleoside triphosphate metabolites as the active forms. Emtricitabine is being tested in COVID-19 patients in combination with tenofovir disoproxil or tenofovir alafenamide. The activation schemes for tenofovir disoproxil or tenofovir alafenamide are provided in the supplementary document."}